ProShares Ultra NASDAQ Biotechnology
BIB
BIB
27 hedge funds and large institutions have $15.6M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
31% less call options, than puts
Call options by funds: $8.63M | Put options by funds: $12.5M
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Holders
27
Holding in Top 10
–
Calls
$8.63M
Puts
$12.5M
Top Buyers
| 1 | +$1M | |
| 2 | +$282K | |
| 3 | +$31.9K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$11K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
+$7.21K |
Top Sellers
| 1 | -$2.49M | |
| 2 | -$1.52M | |
| 3 | -$1.33M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$923K |
| 5 |
Morgan Stanley
New York
|
-$67.4K |